Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Oct 28;13(10):709-714.
doi: 10.1093/ehjacc/zuae098.

Epidemiology of cardiogenic shock using the Shock Academic Research Consortium (SHARC) consensus definitions

Affiliations
Multicenter Study

Epidemiology of cardiogenic shock using the Shock Academic Research Consortium (SHARC) consensus definitions

David D Berg et al. Eur Heart J Acute Cardiovasc Care. .

Abstract

Aims: The Shock Academic Research Consortium (SHARC) recently proposed pragmatic consensus definitions to standardize classification of cardiogenic shock (CS) in registries and clinical trials. We aimed to describe contemporary CS epidemiology using the SHARC definitions in a cardiac intensive care unit (CICU) population.

Methods and results: The Critical Care Cardiology Trials Network (CCCTN) is a multinational research network of advanced CICUs coordinated by the TIMI Study Group (Boston, MA). Cardiogenic shock was defined as a cardiac disorder resulting in SBP < 90 mmHg for ≥30 min [or the need for vasopressors, inotropes, or mechanical circulatory support (MCS) to maintain SBP ≥ 90 mmHg] with evidence of hypoperfusion. Primary aetiologic categories included acute myocardial infarction-related CS (AMI-CS), heart failure-related CS (HF-CS), and non-myocardial (secondary) CS. Post-cardiotomy CS was not included. Heart failure-related CS was further subcategorized as de novo vs. acute-on-chronic HF-CS. Patients with both cardiogenic and non-cardiogenic components of shock were classified separately as mixed CS. Of 8974 patients meeting shock criteria (2017-23), 65% had isolated CS and 17% had mixed shock. Among patients with CS (n = 5869), 27% had AMI-CS (65% STEMI), 59% HF-CS (72% acute-on-chronic, 28% de novo), and 14% secondary CS. Patients with AMI-CS and de novo HF-CS were most likely to have had concomitant cardiac arrest (P < 0.001). Patients with AMI-CS and mixed CS were most likely to present in more severe shock stages (SCAI D or E; P < 0.001). Temporary MCS use was highest in AMI-CS (59%). In-hospital mortality was highest in mixed CS (48%), followed by AMI-CS (41%), similar in de novo HF-CS (31%) and secondary CS (31%), and lowest in acute-on-chronic HF-CS (25%; P < 0.001).

Conclusion: SHARC consensus definitions for CS classification can be pragmatically applied in contemporary registries and reveal discrete subpopulations of CS with distinct phenotypes and outcomes that may be relevant to clinical practice and future research.

Keywords: Cardiac intensive care unit; Cardiogenic shock; Epidemiology.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: D.D.B., E.A.B., S.M.P., V.M.B.-Z., J.-G.P., and D.A.M. are members of the TIMI Study Group, which has received institutional research grant support through Brigham and Women’s Hospital from Abbott, Abiomed, Amgen, Anthos Therapeutics, ARCA Biopharma, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc., Daiichi-Sankyo, Eisai, Intarcia, Ionis Pharmaceuticals, Inc., Janssen Research and Development, LLC, MedImmune, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Roche, Siemens Healthcare Diagnostics, Inc., Softcell Medical Limited, The Medicines Company, and Zora Biosciences. D.D.B. has received consulting fees from AstraZeneca, Pfizer, Mobility Bio, Inc., and Youngene Therapeutics; honoraria from the Metabolic Endocrine Education Foundation, and USV Private Limited; and participates on clinical endpoint committees for studies sponsored by Beckman Coulter, Kowa Pharmaceuticals, Novo Nordisk, and Tosoh Biosciences. L.S. reports speakers bureaus for Abiomed.

Figures

Figure 1
Figure 1
Shock profile and aetiology in a cardiac intensive care unit (CICU) population. Shock cases were classified according to primary haemodynamic profile. Cardiogenic shock (CS) cases were sub-classified according to primary aetiology. Mixed shock indicates that more than one shock category substantially contributed to the haemodynamic profile, and mixed CS refers to mixed shock cases with a known cardiogenic component (∼93% of all mixed shock). Cases for which the shock category was uncertain (n = 188; 2% of all shock cases) are not included in the figure. AMI-CS, acute myocardial infarction-related cardiogenic shock; CS, cardiogenic shock; HF-CS, heart failure-related cardiogenic shock.
Figure 2
Figure 2
In-hospital mortality by shock profile and aetiology. Error bars indicate the 95% confidence intervals around the in-hospital mortality estimates for each shock category. AMI-CS, acute myocardial infarction-related cardiogenic shock; CS, cardiogenic shock; HF-CS, heart failure-related cardiogenic shock.

References

    1. Berg DD, Bohula EA, van Diepen S, Katz JN, Alviar CL, Baird-Zars VM, et al. . Epidemiology of shock in contemporary cardiac intensive care units. Circ Cardiovasc Qual Outcomes 2019;12:e005618. - PMC - PubMed
    1. Bhatt AS, Berg DD, Bohula EA, Alviar CL, Baird-Zars VM, Barnett CF, et al. . De novo vs acute-on-chronic presentations of heart failure-related cardiogenic shock: insights from the critical care cardiology trials network registry. J Card Fail 2021;27:1073–1081. - PMC - PubMed
    1. Zweck E, Thayer KL, Helgestad OKL, Kanwar M, Ayouty M, Garan AR, et al. . Phenotyping cardiogenic shock. J Am Heart Assoc 2021;10:e020085. - PMC - PubMed
    1. Thayer KL, Zweck E, Ayouty M, Garan AR, Hernandez-Montfort J, Mahr C, et al. . Invasive hemodynamic assessment and classification of in-hospital mortality risk among patients with cardiogenic shock. Circ Heart Fail 2020;13:e007099. - PMC - PubMed
    1. Berg DD, Kaur G, Bohula EA, Baird-Zars VM, Alviar CL, Barnett CF, et al. . Prognostic significance of haemodynamic parameters in patients with cardiogenic shock. Eur Heart J Acute Cardiovasc Care 2023;12:651–660. - PMC - PubMed

Publication types